Blood Test May Predict Course of MS
Scientists have discovered a blood test that could predict the course of multiple sclerosis (MS), or even indicate who is likely to develop the condition after a first MS-like attack. The results of the study suggest that differing antibody levels produced in response to the common virus Epstein Barr Virus (EBV), may predict the course of MS. If proven in further studies, this would be the first credible biological indicator, or biomarker, identified for MS that could predict disability progression from a simple blood test.
The work was carried out at the Institute of Neurology, UCL and the Institute of Cell and Molecular Biology, Barts and The London and was funded by the MS Society.
The paper's lead author, Clinical Research Fellow DrRachel Farrell, said: "All the participants in our study had previous history of infection with EBV, which has been shown in other studies and is not surprising given that a large majority of the adult population is infected with EBV. What was surprising is that the levels of a molecule in the blood called anti-EBNA-1 IgG, induced by the virus, were associated with the activity of MS.
"The results of this work show that those participants who had new areas of MS damage in the brain also had high levels of the anti-EBNA-1 IgG molecule in their blood. In addition, participants with higher levels of EBNA-1 in the bloodstream were more likely to have an increase over time in the disability associated with MS."
The researchers received funding of nearly GBP 35,000from the MS Society's Innovation Research grant scheme and looked at 100 participants, 50 of whom had a single MS-like attack but no diagnosis of MS, 25 people with relapsing remitting MS and 25 with primary progressive MS.
They tested participants for evidence of EBV infection in the blood and also looked for anti-EBNA-1 IgG and other EBV induced antibodies. MRI brain scans of each participant were taken over a five year period and the scientists also measured disability progression.
The authors of the study, published in the journal Neurology, concluded that anti-EBNA-1 IgG is a potential biomarker in MS that might be useful in predicting disability and progression. They added that the work needed to be validated in larger studies and in combination with other as yet unidentified biomarkers.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
